目的 探討宮頸癌漏診的原因及特點(diǎn)，提高首診診斷率。 方法 回顧性分析2009年1月－2011年3月收治的外院漏診的65例宮頸癌患者臨床資料。 結(jié)果 漏診的65例中有51例誤診為宮頸糜爛，其中僅13例首診曾行細(xì)胞學(xué)篩查，16例行陰道鏡檢查及活檢，總平均年齡僅39歲，農(nóng)村居民54例。 結(jié)論 各地區(qū)應(yīng)加強(qiáng)宮頸癌篩查意識(shí)，采取相應(yīng)措施及適合的篩查方式提高宮頸癌篩查率，減少漏診。
引用本文： 諶福霞,方芳,馮丹. 宮頸癌漏診病例分析. 華西醫(yī)學(xué), 2012, 27(4): 564-566. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《華西醫(yī)學(xué)》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2002, 55(2): 74-108. |
| 2. | Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK[J]. Lancet, 2004, 364(9430): 249-256. |
| 3. | Sauvaget C. Fayette JM. Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening[J]. Int J Gynecol Obstet, 2011, 113(1): 14-24. |
| 4. | Everett T, Bryant A, Griffin MF, et al. Interventions targeted at women to encourage the uptake of cervical screening[J]. Cochrane Database Syst Rev, 2011(5): CD002834. |
| 5. | IARC Working Group on evaluation ofcervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervicalcytology and its implication for screening policies[J]. Br Med J, 1986, 293(6548): 659-664. |
| 6. | 田淑貞, 竇拉加. HPV檢測(cè)和TCT在宮頸病變篩查及治療后隨訪中的應(yīng)用[J]. 腫瘤基礎(chǔ)與臨床, 2009, 22(5): 455-457. |
| 7. | Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors:a randomized controlled trial[J]. JAMA, 2009, 302(16): 1757-1765. |
| 8. | Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology:overall results of new technologies for cervical cancer screening:randomised controlled trial[J]. BMJ, 2007, 335(7609): 28. |
| 9. | de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11(11): 1048-1056. |
| 10. | Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer[J]. NEJM, 2007, 357(16): 1579-1588. |
| 11. | Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening[J]. Obstet Gynecol, 2004, 103(2): 304-309. |
| 12. | Reich O, Pickel H, Tamussino K, et al. Microinvasive carcinoma of the cervix: site of first focus of invasion[J]. Obstet Gynecol, 2001, 97(6): 890-892. |
| 13. | Solomon D, Stoler M, Jeronimo J, et al. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities[J]. Obstet Gynecol, 2007, 110(2): 288-295. |
- 1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2002, 55(2): 74-108.
- 2. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK[J]. Lancet, 2004, 364(9430): 249-256.
- 3. Sauvaget C. Fayette JM. Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening[J]. Int J Gynecol Obstet, 2011, 113(1): 14-24.
- 4. Everett T, Bryant A, Griffin MF, et al. Interventions targeted at women to encourage the uptake of cervical screening[J]. Cochrane Database Syst Rev, 2011(5): CD002834.
- 5. IARC Working Group on evaluation ofcervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervicalcytology and its implication for screening policies[J]. Br Med J, 1986, 293(6548): 659-664.
- 6. 田淑貞, 竇拉加. HPV檢測(cè)和TCT在宮頸病變篩查及治療后隨訪中的應(yīng)用[J]. 腫瘤基礎(chǔ)與臨床, 2009, 22(5): 455-457.
- 7. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors:a randomized controlled trial[J]. JAMA, 2009, 302(16): 1757-1765.
- 8. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology:overall results of new technologies for cervical cancer screening:randomised controlled trial[J]. BMJ, 2007, 335(7609): 28.
- 9. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11(11): 1048-1056.
- 10. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer[J]. NEJM, 2007, 357(16): 1579-1588.
- 11. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening[J]. Obstet Gynecol, 2004, 103(2): 304-309.
- 12. Reich O, Pickel H, Tamussino K, et al. Microinvasive carcinoma of the cervix: site of first focus of invasion[J]. Obstet Gynecol, 2001, 97(6): 890-892.
- 13. Solomon D, Stoler M, Jeronimo J, et al. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities[J]. Obstet Gynecol, 2007, 110(2): 288-295.